Another Heart Drug Fails, Shocking Cardiologists
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Another Heart Drug Fails, Shocking Cardiologists" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, statnews.com, Reuters and Novartis. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 45d ago.
Quick answers
Why is "Another Heart Drug Fails, Shocking Cardiologists" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- NVS, IONS, AMGN Stocks Drop After-Hours Yahoo Finance · 45d ago
- Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Business Wire · 45d ago
- Novartis announces Lp(a)HORIZON Phase III topline results GlobeNewswire · 45d ago
- Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal WSJ · 45d ago
- Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint WSJ · 45d ago
- Novartis Drug Fails Key Test for New Heart Disease Approach Bloomberg.com · 45d ago
- Novartis’ experimental cardiovascular drug fails a pivotal study statnews.com · 45d ago
- Ionis, Novartis' key experimental heart drug fails in late-stage trial Reuters · 45d ago
- Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Novartis · 45d ago
- Another Heart Drug Fails, Shocking Cardiologists nytimes.com · 45d ago
Topics
Related trends
‘Toy Story’ Star Accused of Shocking Elder Abuse
5 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Inside the Plague Research Labs at the Heart of a Russian Mystery
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Oregon 17, Nebraska 14: Another Fourth Quarter, Another Nebraska Football Meltdown
4 news sources are covering this Sports story right now — PULSE is tracking how fast it spreads.
We Need To Talk About The Shocking Reveal In CRYSTAL LAKE
Audiences and critics are dissecting the shocking reveals, controversial changes, and standout performances in Peacock's prequel series Crystal Lake.
Another LIV Golf player reveals he wants to stay
Rory McIlroy opens the door to a potential PGA Tour comeback for specific LIV Golf players according to Yahoo Sports.
Berkshire Hathaway Just Bet Another $330 Million on One Stock. It Soared 41%
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.